Phase III Study of BAY 43-9006 in Patients With Advanced Hepatocellular Carcinoma Treated After Transcatheter Arterial Chemoembolization (TACE).
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Bayer
- 09 Jun 2011 Results published in the European Journal of Cancer.
- 22 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 24 Jan 2010 Primary endpoint 'Time to disease recurrence' has not been met. No significant difference was found between sorafenib and placebo recipients in the central review. Results presented at ASCO 2010 Gastrointestinal Cancers Symposium.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History